| Literature DB >> 31810309 |
Jingjing Lan1,2, Ruihua Zhang1,2, Pengfei Li1, Junhao Chen1,3, Zhijing Xie1,2, Shijin Jiang1,2.
Abstract
Duck astrovirus type 1 (DAstV-1) infection constitutes a cause of viral hepatitis in ducklings and little is known about the B-cell epitope of DAstV-1. In this study, a monoclonal antibody (mAb) 3D2 against open reading frame 2 (ORF2) protein of DAstV-1 was used to identify the possible epitope in the four serotypes of DAstV. The mAb 3D2 showed no neutralization activity to DAstV-1, and reacted with the conserved linear B-cell epitopes of 454STTESA459 in DAstV-1 ORF2 protein. Sequence analysis, dot blot assay, and cross-reactivity test indicated that the epitope peptide was highly conserved in DAstV-1 sequence and mAb 3D2 had no cross-reactivity with other DAstV serotypes. To the best of our knowledge, this is the first report about identification of the specific conserved linear B-cell epitope of DAstV-1, which will facilitate the serologic diagnosis of DAstV-1 infection.Entities:
Keywords: B-cell epitope; DAstV-1; ORF2 protein; mAb
Year: 2019 PMID: 31810309 PMCID: PMC6940979 DOI: 10.3390/ani9121069
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Primers for expression the complete ORF2 protein of the four serotypes of duck astrovirus (DAstV).
| Primers | Sequence (5′→3′) | AA Position in ORF2 Protein |
|---|---|---|
| D51-ORF2-F | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–732 |
| D51-ORF2-R | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| SL1-ORF2-F | CCGGAATTCATGGTGGCGGCGATGGCCGA | 1–727 |
| SL1-ORF2-R | CCGCTCGAGCTACTCGGCGTGGCCTCCAC | |
| CPH-ORF2-F | CCGGAATTCATGGCCGATAAGGCTGTTGT | 1–746 |
| CPH-ORF2-R | CCGCTCGAGCTACTCGGCGTGGCCACGGC | |
| YP2-ORF2-F | CCGGAATTCATGACTGGGGCCACCCCAA | 1–728 |
| YP2-ORF2-R | CCGCTCGAGCTACTCGGCGTGGCCGCGGC |
Note: EcoR I and Xho I restriction enzyme sites were introduced at the 5′ end of the primers with underlined letters.
Primers for identification of the linear epitope in DAstV-1 D51 strain.
|
|
|
|
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–280 |
| ORF2-AR | CCGCTCGAGAGTGTAGTTATTTGAAATC | |
| ORF2-BF | CCGGAATTCACCAGTGTTCTCTTTTTGGT | 248–494 |
| ORF2-BR | CCGCTCGAGAGACTTCTGTCTGCCATTGT | |
| ORF2-CF | CCGGAATTCCTAATGATTGCAGCTATACC | 461–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–370 |
| ORF2-IR | CCGCTCGAGGGCATCATTGGCAGCACCA | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–451 |
| ORF2-IIR | CCGCTCGAGTTGACCACGAAAGTCATAAAT | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–461 |
| ORF2-IIIR | CCGCTCGAGTAGTGCTGCTGATTCTGTG | |
| ORF2-IVF | CCGGAATTCTACTTGCCCTTGCCTCTCGC | 430–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| ORF2-VF | CCGGAATTCAGAATCAGCACCACAGAATC | 452–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–460 |
| ORF2-1R | CCGCTCGAGTGCTGCTGATTCTGTGGTGC | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–459 |
| ORF2-2R | CCGCTCGAGTGCTGATTCTGTGGTGCTGA | |
| ORF2-AF | CCGGAATTCATGGCTGGTGAGGCCCTTG | 1–458 |
| ORF2-3R | CCGCTCGAGTGATTCTGTGGTGCTGATTC | |
| ORF2-4F | CCGGAATTCATCAGCACCACAGAATCAG | 453–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| ORF2-5F | CCGGAATTCAGCACCACAGAATCAGCAG | 454–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT | |
| ORF2-6F | CCGGAATTCACCACAGAATCAGCAGCACT | 455–732 |
| ORF2-CR | CCGCTCGAGCTACTCGGCGTGGCCGCGGCT |
Note: EcoR I and Xho I restriction enzyme sites were introduced at the 5′ end of the primers with underlined letters.
Figure 1Schematic representation of the mutant DAstV-1 used in this study.
Primers for mutation in the DNA-Launched infectious clone of DAstV-1.
| Product Name | Primers | Sequence (5′→3′) |
|---|---|---|
| Upstream | U-F | GGAAGATCTGGAGGCTGTTGAACCG |
| U-R | GATTCTTTGACCACGAAAGTCATAA | |
| Downstream | D-F | GCACTAATGATTGCAGCTATACCAC |
| D-R | TCCCCGCGGCTGCTGGCAGCTTGTTGT | |
| Delete epitope | UF-1R | ATTTGCTTGTGGTATAGCTGCAATCATTAGTGCTGCACCACGAAAGTCATAAATCA |
| DR-1F | CAGTATACACCACACATGATTTATGACTTTCGTGGTGCAGCACTAATGATTGCAGC | |
| STTESA-GDWQSN | UF-2R | GTGCTGCTGATTCTGTGGTGCTATTACTCTGCCAATCACCGATTCTTTGACCACGAAAG |
| DR-2F | TGACTTTCGTGGTCAAAGAATCGGTGATTGGCAGAGTAATGCACTAATGATTGCAGCTA | |
| STTESA-DSWKSH | UF-3R | GGTATAGCTGCAATCATTAGTGCGTGGCTCTTCCATGAATCGATTCTTTGACCACGAAAG |
| DR-3F | ATGACTTTCGTGGTCAAAGAATCGATTCATGGAAGAGCCACGCACTAATGATTGCAGCT | |
| STTESA-TNWNGN | UF-4R | TGGTATAGCTGCAATCATTAGTGCATTGCCATTCCAGTTGGTGATTCTTTGACCACGAA |
| DR-4F | ATGACTTTCGTGGTCAAAGAATCACCAACTGGAATGGCAATGCACTAATGATTGCAGCT |
Note: Bgl II and Sac II restriction enzyme sites were introduced with the underlined letters.
Figure 2Reactivity analysis of monoclonal antibody (mAb) 3D2. (A) The specificity of the mAb 3D2 to the recombinant glutathione S-transferase tagged ORF2 (GST-ORF2) proteins of the four serotypes of DAstV was detected by dot blotting. The mAb 3D2 specifically reacted with GST-D51 ORF2, while not with GST-SL1 ORF2, GST-CPH ORF2 and GST-YP2 ORF2; (B) Reactivity of mAb 3D2 using indirect immunofluorescence assay (IFA).
Figure 3Neutralization assay of mAb 3D2. (A) The duck embryo fibroblasts (DEF) cells were infected with virus-mAb mixture (v:v, 1:1; dilution of mAb 3D2: 1:10); (B) the DEF cells were infected with virus-mAb mixture (v:v, 1:1; dilution of mAb 3D2: 1:20); (C) the DEF cells were infected with virus-mAb mixture (v:v, 1:1; dilution of mAb 3D2: 1:40); (D) the DEF cells were infected with virus-mAb mixture (v:v, 1:1; dilution of mAb 3D2: 1:80); (E) the DEF cells were infected with virus-mAb mixture (v:v, 1:1; dilution of mAb 3D2: 1:160); (F) the negative control.
Figure 4Screening of the B-cell linear epitope against mAb 3D2. (A,B) Preliminary screening the epitope using dot-blot with mAb 3D2 and anti-GST antibody being the primary antibody; (C) the accurate confirmation of the linear epitope by reducing the amino acids either from the N-terminal or the C-terminal.
Figure 5Schematic diagram of the dot blot test.
Figure 6Sequencing alignment of DAstV strains around the epitope-coding region of the ORF2 protein. DAstV-1 C-NGB strain sequences are shown at the top; the dot indicates identical amino acids of the epitope. The amino acid in the rectangle indicates the epitope.
Figure 7Cross-reactivity analysis in baby hamster kidney (BHK -21) cells by IFA with the DAstV-1 positive sera and the mAb 3D2. (A) BHK-21 cells infected by DNA-launch infection clone of DAstV-1; (B) BHK-21 cells infected by DAstV-1 with the deleted epitope; (C) BHK-21 cells infected by the epitope substituted with ‘GDWQSN’; (D) BHK-21 cells infected by the epitope substituted with ‘DSWKSH’; (E) BHK-21 cells infected by the epitope substituted with ‘TNWNGN’; (F) the normal BHK-21 cells.